A Comparison of Cyclophosphamide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma

被引：0
|
作者：
Figueiredo, Amarilis [1 ]
Atkins, Harold [1 ,2 ,3 ,4 ]
Mallick, Ranjeeta [5 ,6 ]
Kekre, Natasha [1 ,2 ,3 ,4 ]
Kew, Andrea [2 ,3 ,4 ]
McCurdy, Arleigh [1 ,3 ,4 ]
机构：
[1] Ottawa Hosp Res Inst, Ottawa, ON, Canada
[2] Ottawa Hosp, Div Hematol, Ottawa, ON, Canada
[3] Ottawa Hosp, Dept Med, Ottawa, ON, Canada
[4] Univ Ottawa, Ottawa, ON, Canada
[5] Univ Ottawa, Sch Epidemiol, Publ Hlth & Prevent Med, Ottawa, ON, Canada
[6] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.4519.4519
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4519
引用
收藏
页数：5
相关论文
共 50 条
  • [1] A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma
    Khan, Meaghan L.
    Reeder, Craig B.
    Kumar, Shaji K.
    Lacy, Marthy Q.
    Reece, Donna E.
    Dispenzieri, Angela
    Gertz, Morie A.
    Greipp, Phillip
    Hayman, Suzanne
    Zeldenhurst, Steven
    Dingli, David
    Lust, John
    Russell, Stephen
    Laumann, Kristina M.
    Mikhael, Joseph R.
    Bergsagel, P. Leif
    Fonseca, Rafael
    Rajkumar, S. Vincent
    Stewart, A. Keith
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 156 (03) : 326 - 333
  • [2] Cyclophosphamide-bortezomib-dexamethasone compared with bortezomib-dexamethasone in transplantation-eligible patients with newly diagnosed multiple myeloma
    Figueiredo, A.
    Atkins, H.
    Mallick, R.
    Kekre, N.
    Kew, A.
    McCurdy, A.
    CURRENT ONCOLOGY, 2020, 27 (02) : E81 - E85
  • [3] Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
    Crusoe, Edvan De Queiroz
    Higashi, Fabiana
    Martinez, Gracia
    Bittencourt, Rosane
    Pinto Neto, Jorge Vaz
    Sousa, Lais
    Santucci, Rodrigo
    Pessoa Magalhaes, Roberto Jose
    Colli, Gilberto
    Marques Nunes, Renata Ferreira
    Ribeiro, Glaciano
    Nicacio, Jandir
    Zanella, Karla Richter
    Kutner, Jose Mauro
    Magalhaes, Andre
    Leao, Danielle
    Hallack Neto, Abrahao Elias
    Braga, Walter
    Souza, Emanuella G.
    Guimaraes, Antonio Julio A. M.
    Durigon, Giovanna Steffenello
    Laks, Dani
    Maiolino, Angelo
    de Moraes Hungria, Vania Tietsche
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2020, 42 (02) : 118 - 124
  • [4] Induction Therapy with Bortezomib-Cyclophosphamide-Dexamethasone (BCD) for Newly Diagnosed Transplant Eligible Patients with Multiple Myeloma
    Tsukada, Nobuhiro
    Ikeda, Masahiro
    Shingaki, Sumito
    Miyazaki, Kanji
    Meshitsuka, Sosuke
    Abe, Yu
    Yoshiki, Yumiko
    Suzuki, Kenshi
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (02) : S205 - S205
  • [5] Comparison of lenalidomide, bortezomib, dexamethasone vs bortezomib, cyclophosphamide, dexamethasone as an induction regimen in newly diagnosed myeloma patients eligible for intensive chemotherapy
    Van de Wyngaert, Zoe
    Malard, Florent
    Marjanovitch, Zora
    Alsuliman, Tamim
    Ikhlef, Souhila
    Mohty, Mohamad
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S137 - S137
  • [6] Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma
    Liang, Dong
    Bai, Shenrui
    Feng, Demei
    Chen, Guanjun
    Liang, Yang
    Wang, Hua
    BMC CANCER, 2024, 24 (01)
  • [7] Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) Compared to Bortezomib-Dexamethasone (Vel-Dex) As Induction Therapy for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma
    Lavoie-Gagnon, Claudie
    St-Gelais, Jonathan
    Adam, Jean-Philippe
    Viens, Daniel
    Gagne, Felixe
    Decarie, Yann
    Lemieux-Blanchard, Emilie
    BLOOD, 2017, 130
  • [8] An Adjusted Treatment Comparison of Bortezomib/Cyclophosphamide/Dexamethasone and Bortezomib/Thalidomide/Dexamethasone from Real-World Data in Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible
    Mehra, Maneesha
    Cote, Sarah
    Kampfenkel, Tobias
    Nair, Sandhya
    BLOOD, 2019, 134
  • [9] Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis
    Wang, Yin-Che
    Lin, Cheng-Hsien
    Su, Yu-Chen
    Teng, Chieh-Lin Jerry
    HEMATOLOGY, 2025, 30 (01)
  • [10] Superiority of Triple Combination Bortezomib plus Cyclophosphamide and Dexamethasone (VCD) Versus Thalidomide plus Cyclophosphamide and Dexamethasone (CTD) in Newly Diagnosed Multiple Myeloma Transplant-Eligible Patients
    Crusoe, Edvan De Queiroz
    Higashi, Fabiana
    Martinez, Gracia
    Bittencourt, Rosane
    Maiolino, Angelo
    Sousa, Lais
    Nunes, Renata Ferreira Marques
    Ribeiro, Glaciano
    Nicacio, Jandir
    Zanella, Karla Richter
    Magalhaes, Andre
    Leao, Danielle
    Pinto Neto, Jorge Vaz
    Hallack Neto, Abrahao Elias
    Braga, Walter
    Souza, Emmanuella G.
    Guimaraes, Antonio Julio A. M.
    Durigon, Giovanna Steffenello
    Laks, Dani
    Kutner, Jose Mauro
    Colli, Gilberto
    Santucci, Rodrigo
    Magalhaes, Roberto Jose Pessoa
    Hungria, Vania T. M.
    BLOOD, 2017, 130
12345